• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    Inari Medical to Announce Third Quarter 2024 Financial Results

    10/7/24 4:05:00 PM ET
    $NARI
    Medical/Dental Instruments
    Health Care
    Get the next $NARI alert in real time by email

    IRVINE, Calif., Oct. 07, 2024 (GLOBE NEWSWIRE) -- Inari Medical, Inc. (NASDAQ:NARI) ("Inari"), a medical device company with a mission to treat and transform the lives of patients suffering from venous and other diseases, today announced that it will release its third quarter 2024 financial results on Monday, October 28, 2024. In conjunction with the release, Inari will host a conference call and webcast at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time to discuss its financial results and recent highlights.

    Interested parties may access the live earnings call via telephone by dialing 844-825-9789 for domestic callers or 412-317-5180 for international callers. The live webinar may be accessed by visiting the Events Section of the Inari investor relations website or by registering here. A replay of the webinar will be available shortly after the conclusion of the call and will be archived on Inari's website.

    About Inari Medical, Inc.

    Patients first. No small plans. Take care of each other. These are the guiding principles that form the ethos of Inari Medical. We are committed to improving lives in extraordinary ways by creating innovative solutions for both unmet and underserved health needs. In addition to our purpose-built solutions, we leverage our capabilities in education, clinical research, and program development to improve patient outcomes. We are passionate about our mission to establish our treatments as the standard of care for venous disease, including venous thromboembolism, chronic venous disease and beyond. We are just getting started. Learn more at www.inarimedical.com and connect with us on LinkedIn, X (Twitter), and Instagram.

    Investor Contact:

    Marissa Bych

    Gilmartin Group LLC

    [email protected]



    Primary Logo

    Get the next $NARI alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $NARI

    DatePrice TargetRatingAnalyst
    12/17/2024$75.00Outperform
    Oppenheimer
    9/18/2024$50.00Hold
    Stifel
    9/3/2024$47.00Market Perform
    Leerink Partners
    8/9/2024$68.00Buy
    Deutsche Bank
    7/25/2024Outperform
    William Blair
    7/18/2024Buy → Hold
    Needham
    2/29/2024$85.00 → $55.00Overweight → Neutral
    Piper Sandler
    1/23/2024$72.00Buy
    Needham
    More analyst ratings

    $NARI
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Oppenheimer initiated coverage on Inari with a new price target

      Oppenheimer initiated coverage of Inari with a rating of Outperform and set a new price target of $75.00

      12/17/24 7:53:14 AM ET
      $NARI
      Medical/Dental Instruments
      Health Care
    • Stifel initiated coverage on Inari with a new price target

      Stifel initiated coverage of Inari with a rating of Hold and set a new price target of $50.00

      9/18/24 7:45:45 AM ET
      $NARI
      Medical/Dental Instruments
      Health Care
    • Leerink Partners initiated coverage on Inari with a new price target

      Leerink Partners initiated coverage of Inari with a rating of Market Perform and set a new price target of $47.00

      9/3/24 8:10:13 AM ET
      $NARI
      Medical/Dental Instruments
      Health Care